NDGA

SKU: orb1297668

Description

Nordihydroguaiaretic acid

Research Area

Cell Biology, Metabolism Research

Key Properties

• CAS Number: 500-38-9
• MW: 302.4
• Purity: >97%
• Formula: C₁₈H₂₂O₄
• SMILES: CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1
• Target: LO (Lipoxygenase)
• Solubility: Soluble in Ethanol (up to 50 mg/ml)

Bioactivity

• Target IC50:
  MDA-MB-435 cells proliferation:38.8 ± 2.1 μM|P388 cells apoptosis:0.66 μg/mL|SKBR3 cells proliferation:31.09 ± 1.6 μM|5-LOX:8 ± 3 μM
• In Vivo:
  METHODS: To assess the activity and efficacy of Voxelotor, Voxelotor (100-150 mg/kg, 0.5% methylcellulose/0.5% SDS) was administered by gavage to a mouse model of SCD twice daily for 9-12 days. RESULTS: Voxelotor reduced isolated sickle cells and prolonged erythrocyte half-life in the SCD mouse model.
• In Vitro:
  METHODS: Voxelotor (3-30 µmol/L) was incubated with hemoglobin (25 µmol/L) in TES or saline buffer at 37 ℃ for 45 min, and changes in the binding affinity of O2 for Hb were measured using a TCS hematology analyzer. RESULTS: Voxelotor, a small molecule that binds to the N-terminal α-chain of Hb, increases the affinity of HbS for oxygen, delays HbS polymerization in vitro and prevents erythrocyte sickling. METHODS: HepG2 cells were treated with Voxelotor (1 µg/mL) and their metabolites were analyzed by liquid chromatography, high resolution MS and tandem MS. RESULTS: Voxelotor can be used for the identification of phase I and phase II metabolites in vitro.

Storage & Handling

• Storage: RT
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Dihydronorguaiaretic Acid, Autophagy, Antioxidant, NDGA, inhibit, LOX, Lipoxygenase, Nordihydroguaiaretic acid, Inhibitor, Ferroptosis

Compound Identifiers

PubChem CID

4534